Telix Price Earnings To Growth Ratio from 2010 to 2024

TLX Stock   15.76  0.16  1.03%   
Telix Pharmaceuticals Price Earnings To Growth Ratio yearly trend continues to be fairly stable with very little volatility. Price Earnings To Growth Ratio will likely drop to 0.04 in 2024. During the period from 2010 to 2024, Telix Pharmaceuticals Price Earnings To Growth Ratio regression line of annual values had r-squared of  0.04 and arithmetic mean of  0.61. View All Fundamentals
 
Price Earnings To Growth Ratio  
First Reported
2010-12-31
Previous Quarter
0.0441
Current Value
0.0419
Quarterly Volatility
1.59548708
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 1.1 M, Depreciation And Amortization of 7.1 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Price Earnings To Growth Ratio Growth Pattern

Below is the plot of the Price Earnings To Growth Ratio of Telix Pharmaceuticals Limited over the last few years. It is Telix Pharmaceuticals' Price Earnings To Growth Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Earnings To Growth Ratio10 Years Trend
Pretty Stable
   Price Earnings To Growth Ratio   
       Timeline  

Telix Price Earnings To Growth Ratio Regression Statistics

Arithmetic Mean0.61
Geometric Mean0.15
Coefficient Of Variation260.87
Mean Deviation0.90
Median0.05
Standard Deviation1.60
Sample Variance2.55
Range6.6559
R-Value(0.20)
Mean Square Error2.63
R-Squared0.04
Significance0.47
Slope(0.07)
Total Sum of Squares35.64

Telix Price Earnings To Growth Ratio History

2024 0.0419
2023 0.0441
2019 0.049
2018 -7.42E-4
2016 6.13
2015 0.97
2014 -0.18

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Price Earnings To Growth Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Earnings To Growth Ratio 0.04  0.04 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.